Table 2.

Association of baseline CKD awareness with health behaviors and chronic disease management at follow-up (N = 3,586).

	Prevalence of Behavior or Medication at Follow-up if CKD Aware (%)	OR (95% CI) Unadjusted	p-value	aOR (95% CI) Model 1	p-value	aOR (95% CI) Model 2	p-value
Health Behaviors
Smoking Avoidance	93.9	1.77 (0.88, 3.54)	0.108	1.16 (0.59,2.30)	0.665	1.33 (0.50, 3.57)	0.563
Exercise	33.6	0.75 (0.53 to 1.06)	0.103	1.00 (0.69, 1.43)	0.977	0.89 (0.60, 1.33)	0.574
NSAID Avoidance	92.0	2.22 (1.17, 4.23)	0.015	1.55 (0.80, 2.99)	0.189	1.41 (0.72, 2.78)	0.317
Chronic Disease Management Indicators
ACEi/ARB Use	45.3	0.69 (0.51, 0.94)	0.017	0.82 (0.60, 1.13)	0.223	0.72 (0.50, 1.03)	0.075
Statin Use	61.1	1.19 (0.85, 1.69)	0.312	1.06 (0.75, 1.48)	0.744	0.79 (0.53, 1.18)	0.255

Model 1: Adjusted for eGFR and UACR.

Model 2: Adjusted for eGFR and UACR + age, sex, race, education, income, insurance status, marital status, urban status, region, hypertension, diabetes, coronary artery disease, stroke, family history of kidney disease, and baseline health behaviors and chronic disease management indicators.

Imputed data used for those who did not complete the follow-up in-home visit.

CKD – chronic kidney disease, OR – odds ratio; CI – confidence interval, aOR – adjusted odds ratio; NSAID – nonsteroidal anti-inflammatory drug; ACEi/ARB - angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.